MSMitsuru Shinohara

Mitsuru Shinohara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mitsuru Shinohara has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Guojun Bu

    Division of Life Science and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology, Clear Water Bay, China

    5 shared publications
  • Guojun Bu

    Department of Neuroscience, Mayo Clinic, Jacksonville, USA

    5 shared publications
  • Ghupurjan Gheni

    Department of Aging Neurobiology, Research Institute, National Center for Geriatrics and Gerontology, Obu, Japan

    4 shared publications
  • Naoyuki Sato

    Department of Aging Neurobiology, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, 7-430, Morioka, Obu, Aichi 474-8511, Japan

    4 shared publications
  • Akio Fukumori

    Department of Aging Neurobiology, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology From the , Obu, Aichi, Japan

    3 shared publications
  • Kaoru Suzuki

    Department of Aging Neurobiology, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology From the , Obu, Aichi, Japan

    3 shared publications

Latest Publications

  • Open Access

    Coordinated regional association of cathepsins and dipeptidyl peptidases with N-truncated Abeta42, Abeta40, and tau in Alzheimer’s brain

    by Mitsuru Shinohara, Ghupurjan Gheni, Kaori Kawai, Maho Morishima, Shigeo Murayama, Yuko Saito, Guojun Bu, Naoyuki Sato

    Regional distributions of amyloid-β (Aβ) and tau accumulation have provided important insights into the pathomechanisms of Alzheimer’s dise

  • Open Access

    Cerebral hypoperfusion reduces tau accumulation

    by Ghupurjan Gheni, Mitsuru Shinohara, Masami Masuda‐Suzukake, Akihiko Shindo, Atsushi Watanabe, Kaori Kawai, Guojun Bu, Hidekazu Tomimoto, Masato Hasegawa, Naoyuki Sato

    Objective: Alzheimer's disease (AD) often coexists with cerebrovascular diseases. However, the impact of cerebrovascular diseases such as stroke on AD pathology remains poorly understood.Methods: This study examines the correlation between cerebrovascular diseases and AD pathology. The research was carried out using clinical and neuropathological data collected from the National Alzheimer's Coordinating Center (NACC) database and an animal model in which bilateral common carotid artery stenosis surgery was performed, following the injection of tau seeds into the brains of wild‐type mice.Results: Analysis of the NACC database suggests that clinical stroke history and lacunar infarcts are associated with lower neurofibrillary tangle pathology. An animal model demonstrates that chronic cerebral hypoperfusion reduces tau pathology, which was observed in not only neurons but also astrocytes, microglia, and oligodendrocytes. Furthermore, we found that astrocytes and microglia were activated in response to tau pathology and chronic cerebral hypoperfusion. Additionally, cerebral hypoperfusion increased a lysosomal enzyme, cathepsin D.Interpretation: These data together indicate that cerebral hypoperfusion reduces tau accumulation likely through an increase in microglial phagocytic activity towards tau and an elevation in degradation through cathepsin D. This study contributes to understanding the relationship between tau pathology and cerebrovascular diseases in older people with multimorbidity.


  • Open Access

    APOEgenotypes modify the obesity paradox in dementia

    by Mitsuru Shinohara, Ghupurjan Gheni, Junichi Hitomi, Guojun Bu, Naoyuki Sato

    Background: While obesity in midlife is a risk factor for dementia, several studies suggested that obesity also protected against dementia, hence so-called obesity paradox. The current study aims to address the relationship between apolipoprotein E (APOE) genotype and obesity in dementia.Methods: Clinical and neuropathological records of the National Alzheimer’s Coordinating Center (NACC) in the USA, which longitudinally followed approximately 20 000 subjects with different cognitive statues,APOEgenotype and obesity states, were reviewed.Results: Obesity was associated with cognitive decline in early elderly cognitively normal individuals withoutAPOE4, especially those withAPOE2. Neuropathological analyses adjusted for dementia status showed thatAPOE2carriers tended to have more microinfarcts and haemorrhages due to obesity. On the other hand, obesity was associated with a lower frequency of dementia and less cognitive impairment in individuals with mild cognitive impairment or dementia. Such trends were particularly strong inAPOE4carriers. Obesity was associated with fewer Alzheimer’s pathologies in individuals with dementia.Conclusions: Obesity may accelerate cognitive decline in middle to early elderly cognitive normal individuals withoutAPOE4likely by provoking vascular impairments. On the other hand, obesity may ease cognitive impairment in both individuals with dementia and individuals at the predementia stage, especially those withAPOE4, through protecting against Alzheimer’s pathologies. These results support thatAPOEgenotype modifies the obesity paradox in dementia.


  • Open Access

    ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease

    by Mitsuru Shinohara, Junko Hirokawa, Akemi Shimodaira, Yoshitaka Tashiro, Kaoru Suzuki, Ghupurjan Gheni, Akio Fukumori, Tomoyasu Matsubara, Maho Morishima, Yuko Saito, et al.

    Despite the routine use of sandwich enzyme-linked immunosorbent assays (ELISAs) for quantifying tau levels in CSF and plasma, tau accumulations in the brains of patients with Alzheimer disease (AD) have rarely been evaluated by this method. Thus, by introducing several tau ELISAs that target different epitopes, we evaluated accumulated tau levels in postmortem brains depending on disease stage, brain areas, and other AD-related changes. Notably, tau levels in insoluble fraction determined by each ELISAs differ depending on the epitopes of antibodies: non-AD control samples yield relatively high signals when an antibody against the N-terminal region of tau is used. On the other hand, ELISAs combining antibodies against the later-middle to C-terminal regions of tau produced substantially increased signals from AD samples, compared to those from non-AD controls. Such ELISAs better distinguish AD and non-AD controls, and the results are more closely associated with Braak neurofibrillary tangles stage, Aβ accumulation, and glial markers. Moreover, these ELISAs can reflect the pattern of tau spread across brain regions. In conclusion, Tau ELISAs that combine antibodies against the later-middle to C-terminal regions of tau can better reflect neuropathological tau accumulation, which would enable to evaluate tau accumulation in the brain at a biochemical level.


  • Open Access

    Characterization of Tau ELISAs for Evaluating Tau Accumulation in the Brains With Alzheimer’s Disease

    by Mitsuru Shinohara, Junko Hirokawa, Akemi Shimodaira, Yoshitaka Tashiro, Kaoru Suzuki, Akio Fukumori, Tomoyasu Matsubara, Maho Morishima, Yuko Saito, Shigeo Murayama, et al.

    Background: One main pathological hallmark of Alzheimer’s disease (AD) is tau accumulation as neurofibrillary tangles (NFTs) in the brain. Although sandwich enzyme-linked immunosorbent assays (ELISAs) are useful for quantifying tau levels, including those in CSF, plasma and brain, it has not yet been determined which antibody combination is the most appropriate for assessing the neuropathological accumulation of tau in the brain. Methods: We developed several sandwich tau ELISAs by introducing antibodies against several tau epitopes, including from its N-terminal and C-terminal regions, and evaluated tau levels depending on disease stage, brain areas, and other AD-related changes. Results: We observed that tau levels in insoluble brain fraction determined by each ELISAs differ depending on the epitopes of the antibodies: there is a trend that non-AD control samples yield relatively high signals when an antibody against the N-terminal region of tau is used. On the other hand, ELISAs combining two antibodies against the later-middle to C-terminal regions of tau produced substantially increased signals from AD samples, compared to those from non-AD controls. Such ELISAs better distinguish AD and non-AD controls, and the results are more closely associated with Braak NFT stage, Aβ accumulation, and neuroinflammatory markers. In addition, these ELISAs can reflect the pattern of tau spread across brain regions. Conclusions: Tau ELISAs that combine two antibodies against the later-middle to C-terminal regions of tau can better reflect neuropathological tau accumulation, which would enable to evaluate tau accumulation in the brain at a biochemical level.

  • Top Cited Papers
    Open Access

    APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease

    by Zonghua Li, Francis Shue, Na Zhao, Mitsuru Shinohara, Guojun Bu

    Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for Alzheimer’s disease (AD), have yielded significant insights into the pathogenic mechanism. Among the three common coding variants,APOE*ε4increases, whereasAPOE*ε2decreases the risk of late-onset AD compared withAPOE*ε3. Despite increased understanding of the detrimental effect ofAPOE*ε4, it remains unclear howAPOE*ε2confers protection against AD. Accumulating evidence suggests thatAPOE*ε2protects against AD through both amyloid-β (Aβ)-dependent and independent mechanisms. In addition,APOE*ε2has been identified as a longevity gene, suggesting a systemic effect ofAPOE*ε2on the aging process. However,APOE*ε2is not entirely benign;APOE*ε2carriers exhibit increased risk of certain cerebrovascular diseases and neurological disorders. Here, we review evidence from both human and animal studies demonstrating the protective effect ofAPOE*ε2against AD and propose a working model depicting potential underlying mechanisms. Finally, we discuss potential therapeutic strategies designed to leverage the protective effect ofAPOE2to treat AD.


  • Open Access

    APOE2 is associated with longevity independent of Alzheimer’s disease

    by Mitsuru Shinohara, Takahisa Kanekiyo, Masaya Tachibana, Aishe Kurti, Motoko Shinohara, Yuan Fu, Jing Zhao, Xianlin Han, Patrick M Sullivan, G William Rebeck, et al.

    Although the ε2 allele of apolipoprotein E (APOE2) benefits longevity, its mechanism is not understood. The protective effects of theAPOE2 on Alzheimer’s disease (AD) risk, particularly through their effects on amyloid or tau accumulation, may confoundAPOE2effects on longevity. Herein, we showed that the association betweenAPOE2and longer lifespan persisted irrespective of AD status, including its neuropathology, by analyzing clinical datasets as well as animal models. Notably,APOE2was associated with preserved activity during aging, which also associated with lifespan. In animal models, distinct apoE isoform levels, whereAPOE2has the highest, were correlated with activity levels, while some forms of cholesterol and triglycerides were associated with apoE and activity levels. These results indicate thatAPOE2can contribute to longevity independent of AD. Preserved activity would be an early-observable feature ofAPOE2-mediated longevity, where higher levels of apoE2 and its-associated lipid metabolism might be involved.


  • Open Access

    APOE2 promotes longevity independent of Alzheimer’s disease

    by Mitsuru Shinohara, Takahisa Kanekiyo, Masaya Tachibana, Aishe Kurti, Motoko Shinohara, Yuan Fu, Jing Zhao, Xianlin Han, Patrick M. Sullivan, William G Rebeck, et al.

    Objective: Although apolipoprotein E ( APOE ) allele associates with longevity, its mechanism is not understood. The protective effects of APOE 2 and the deleterious effects of APOE4 on Alzheimer’s disease (AD) risk may confound APOE effects on longevity. Methods: We analyzed a large number of subjects from the National Alzheimer’s Coordinating Center (NACC), and animal models expressing human apoE isoforms in the absence of AD. Results: Clinically, the APOE2 allele was associated with longer lifespan, while APOE4 associated with shorter lifespan, compared to the common APOE3 allele. This effect was also seen irrespective of clinical AD status, and in subjects with little amyloid pathology or after adjustment for AD-related pathologies. In animal studies, apoE2-TR mice also exhibited longer lifespan, while apoE4 showed some trends of shorter lifespan. Notably, old apoE2-TR mice kept activity measured by open field assay, associated with longer lifespan. Evidence of preserved activity in APOE2 carrier was also obtained in clinical records. In animal studies, higher levels of apoE2 in brain and plasma were correlated with activity. Moreover, lower levels of total cholesterol in the brain and higher levels of high-density lipoprotein cholesterol and triglycerides in the plasma of apoE2-TR mice were associated with apoE levels and more activity. Interpretation: APOE2 can contribute to longevity independent of AD. Preserved activity would be an early-observable feature of apoE2-mediated longevity, where higher levels of apoE2 and its-associated lipid metabolism might be involved.

  • Open Access

    Interaction between APOE genotype and diabetes in cognitive decline

    by Mitsuru Shinohara, Yoshitaka Tashiro, Kaoru Suzuki, Akio Fukumori, Guojun Bu, Naoyuki Sato

    Introduction Although diabetes and apolipoprotein E (apoE) are both significant risk factors for dementia, including Alzheimer's disease, it remains to be clarified how they are related to each other in contributing to the risk of dementia. Methods By reviewing the National Alzheimer's Coordinating Center (NACC) clinical records, we investigated whether diabetes affects cognitive decline depending on APOE genotype and their potential relationships with neuropathology. Results A significant interaction between diabetes and APOE genotype exists, where diabetes affected cognitive decline in APOE3 carriers and APOE2 carriers, but not APOE4 carriers. Moreover, the presence of vascular pathology was increased by diabetes in APOE3 carriers, while APOE4 carriers nearly reached plateau levels irrespective of diabetes. Discussion Diabetes accelerates cognitive decline, in part, through accelerating vascular impairment in non‐APOE ε4 carriers, but such effects are negligible in APOE4 carriers, who themselves are already vulnerable to vascular impairment.


  • The Roles of Apolipoprotein E, Lipids, and Glucose in the Pathogenesis of Alzheimer’s Disease

    by Mitsuru Shinohara, Naoyuki Sato

    Although the mechanisms by which Alzheimer's disease (AD) occurs remains unclear, it is widely accepted that both genetic and nongenetic components contribute to the pathogenesis of AD, especially the sporadic form of the disease. Nongenetic risk factors include diabetes and dyslipidemia, which are associated with impaired glucose and lipid metabolism, respectively. Apolipoprotein E (ApoE), one of the major lipid carriers in the brain, is the strongest genetic risk factor for late-onset AD. Several studies indicate that ApoE isoforms differentially affect not only lipid metabolism but also glucose metabolism or related pathways, suggesting that these risk factors contribute to the pathogenesis of AD through some common mechanisms. In this chapter, we discuss the roles of ApoE, lipids, and glucose in the pathogenesis of AD by considering their potential interactions.